妊娠期血管性血友病的新治疗方法。
New approach of the treatment of von Willebrand's disease during pregnancy.
作者信息
Gojnic Miroslava, Fazlagic A, Likic I, Stefanovic A, Vidakovic S, Pervulov M, Petkovic S, Mostic T, Miljic P, Bogdanovic A
机构信息
Medical Faculty Belgrade, Institute of Gynecology and Obstetrics, Clinical Center of Serbia, University of Belgrade, 38 Milesevska Street, 11000, Belgrade, Serbia and Montenegro.
出版信息
Arch Gynecol Obstet. 2005 Nov;273(1):35-8. doi: 10.1007/s00404-005-0739-x. Epub 2005 Oct 28.
AIM
The aim of the study was to analyze the effectiveness of the application of DDAVP (desmopressin) and Hemate P with cryoprecipitate pre- and postpartum in patients with von Willebrand disease.
METHODS
We monitored 32 patients with von Willebrand disease during the study period 1993-2003. DDAVP was applied in the 36th/37th week of gestation and cryoprecipitate and fresh frozen plasma were applied 1 day before and 3 days after delivery. DDAVP treatment continued for 4 weeks. Factor VIII (Hemate P) at the day of delivery
RESULTS
No complications occurred in the studied population.
CONCLUSION
Precipitation of DDAVP, Hemate P, and cryoprecipitate may help in the treatment of pregnant women with von Willebrand disease.
目的
本研究旨在分析去氨加压素（DDAVP）和人凝血因子Ⅷ（Hemate P）联合冷沉淀在血管性血友病患者产前和产后应用的有效性。
方法
在1993年至2003年的研究期间，我们对32例血管性血友病患者进行了监测。在妊娠第36/37周应用去氨加压素，在分娩前1天和分娩后3天应用冷沉淀和新鲜冰冻血浆。去氨加压素治疗持续4周。分娩当天应用凝血因子Ⅷ（Hemate P）。
结果
研究人群中未发生并发症。
结论
去氨加压素、人凝血因子Ⅷ和冷沉淀联合应用可能有助于治疗血管性血友病孕妇。
Zotero 插件